TY - JOUR
T1 - Preclinical animal models for testing iPSC/ESC-based heart therapy
AU - Stillitano, Francesca
AU - Karakikes, Ioannis
AU - Costa, Kevin D.
AU - Fish, Kenneth
AU - Hajjar, Roger J.
AU - Hulot, Jean Sébastien
PY - 2012
Y1 - 2012
N2 - Embryonic and induced pluripotent stem cell (ESC/iPSC) technologies offer an unprecedented possibility of devising cell replacement therapies for numerous disorders, including cardiovascular diseases. Studies are progressively investigating whether ESC or iPSC can serve to restore physiological function of diseased hearts in vivo. However, the animal model, the population of ESC/iPSC-derived cardiomyocytes and the delivery technique need to be optimized before these cells can be used effectively for cell replacement therapy. In this review, we describe the potential applications, limitations and challenges of iPSC- and ESC-based heart therapies in preclinical animal models.
AB - Embryonic and induced pluripotent stem cell (ESC/iPSC) technologies offer an unprecedented possibility of devising cell replacement therapies for numerous disorders, including cardiovascular diseases. Studies are progressively investigating whether ESC or iPSC can serve to restore physiological function of diseased hearts in vivo. However, the animal model, the population of ESC/iPSC-derived cardiomyocytes and the delivery technique need to be optimized before these cells can be used effectively for cell replacement therapy. In this review, we describe the potential applications, limitations and challenges of iPSC- and ESC-based heart therapies in preclinical animal models.
UR - http://www.scopus.com/inward/record.url?scp=84876690015&partnerID=8YFLogxK
U2 - 10.1016/j.ddmod.2012.04.004
DO - 10.1016/j.ddmod.2012.04.004
M3 - Review article
AN - SCOPUS:84876690015
SN - 1740-6757
VL - 9
SP - e229-e236
JO - Drug Discovery Today: Disease Models
JF - Drug Discovery Today: Disease Models
IS - 4
ER -